Your browser doesn't support javascript.
loading
Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice.
Yao, Zhenyu; Gong, Ying; Chen, Wenbin; Shao, Shanshan; Song, Yongfeng; Guo, Honglin; Li, Qihang; Liu, Sijin; Wang, Ximing; Zhang, Zhenhai; Wang, Qian; Xu, Yunyun; Wu, Yingjie; Wan, Qiang; Zhao, Xinya; Xuan, Qiuhui; Wang, Dawei; Lin, Xiaoyan; Xu, Jiawen; Liu, Jun; Proud, Christopher G; Wang, Xuemin; Yang, Rui; Fu, Lili; Niu, Shaona; Kong, Junjie; Gao, Ling; Bo, Tao; Zhao, Jiajun.
Affiliation
  • Yao Z; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Gong Y; Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, China.
  • Chen W; Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, China.
  • Shao S; Shandong Prevention and Control Engineering Laboratory of Endocrine and Metabolic Diseases, Jinan, China.
  • Song Y; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Guo H; Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, China.
  • Li Q; Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, China.
  • Liu S; Shandong Prevention and Control Engineering Laboratory of Endocrine and Metabolic Diseases, Jinan, China.
  • Wang X; Central Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Zhang Z; Shandong Prevention and Control Engineering Laboratory of Endocrine and Metabolic Diseases, Jinan, China.
  • Wang Q; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Xu Y; Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, China.
  • Wu Y; Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, China.
  • Wan Q; Shandong Prevention and Control Engineering Laboratory of Endocrine and Metabolic Diseases, Jinan, China.
  • Zhao X; Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Xuan Q; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Wang D; Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, China.
  • Lin X; Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, China.
  • Xu J; Shandong Prevention and Control Engineering Laboratory of Endocrine and Metabolic Diseases, Jinan, China.
  • Liu J; Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
  • Proud CG; Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Wang X; Department of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, Jinan, China.
  • Yang R; Department of Ultrasound, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Fu L; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Niu S; Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, China.
  • Kong J; Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, China.
  • Gao L; Shandong Prevention and Control Engineering Laboratory of Endocrine and Metabolic Diseases, Jinan, China.
  • Bo T; Shandong Provincial Hospital, School of Laboratory Animal & Shandong Laboratory Animal Center, Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
  • Zhao J; Institute of Genome Engineered Animal Models, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Nat Metab ; 5(10): 1706-1725, 2023 10.
Article in En | MEDLINE | ID: mdl-37735236
ABSTRACT
Under normal conditions, insulin promotes hepatic de novo lipogenesis (DNL). However, during insulin resistance (IR), when insulin signalling is blunted and accompanied by hyperinsulinaemia, the promotion of hepatic DNL continues unabated and hepatic steatosis increases. Here, we show that WD40 repeat-containing protein 6 (WDR6) promotes hepatic DNL during IR. Mechanistically, WDR6 interacts with the beta-type catalytic subunit of serine/threonine-protein phosphatase 1 (PPP1CB) to facilitate PPP1CB dephosphorylation at Thr316, which subsequently enhances fatty acid synthases transcription through DNA-dependent protein kinase and upstream stimulatory factor 1. Using molecular dynamics simulation analysis, we find a small natural compound, XLIX, that inhibits the interaction of WDR6 with PPP1CB, thus reducing DNL in IR states. Together, these results reveal WDR6 as a promising target for the treatment of hepatic steatosis.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Fatty Liver Limits: Animals Language: En Journal: Nat Metab Year: 2023 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Fatty Liver Limits: Animals Language: En Journal: Nat Metab Year: 2023 Document type: Article Affiliation country: China